Nephrotoxicity is increased in some patients by the concurrent use of ciclosporin
and amikacin, gentamicin or tobramycin. This interaction would be expected with all systemic aminoglycosides
The concurrent use of ciclosporin
should only be undertaken if the clinical
benefit outweighs the risk of renal
damage. Close monitoring of renal
function and aminoglycoside levels is required.